PMID- 29076867
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20220317
IS  - 1538-9804 (Electronic)
IS  - 0162-220X (Print)
IS  - 0162-220X (Linking)
VI  - 42
IP  - 1
DP  - 2019 Jan/Feb
TI  - Patient and Oncology Nurse Preferences for the Treatment Options in Advanced 
      Melanoma: A Discrete Choice Experiment.
PG  - E52-E59
LID - 10.1097/NCC.0000000000000557 [doi]
AB  - BACKGROUND: Understanding the perceptions of patients and oncology nurses about 
      the relative importance of benefits and risks associated with newer treatments of 
      advanced melanoma can help to inform clinical decision-making. OBJECTIVES: The 
      aims of this study were to quantify and compare the views of patients and 
      oncology nurses regarding the importance of attributes of treatments of advanced 
      melanoma. METHODS: A discrete choice experiment (DCE) was conducted in US-based 
      oncology nurses and patients diagnosed with advanced melanoma. Patients and 
      nurses were enlisted through online panels. In a series of scenarios, respondents 
      had to choose between 2 hypothetical treatments, each with 7 attributes: mode of 
      administration (MoA), dosing schedule (DS), median duration of therapy (DoT), 
      objective response rate (ORR), progression-free survival (PFS), overall survival 
      (OS), and grade 3 or 4 adverse events (AEs). Hierarchical Bayesian logistic 
      regression models were used to estimate preference weights. RESULTS: A total of 
      200 patients with advanced melanoma and 150 oncology nurses participated. The 
      relative importance estimates of attributes by patients and nurses, respectively, 
      were as follows: OS, 33% and 28%; AEs, 29% and 26%; ORR, 25% and 27%; PFS, 12% 
      and 15%; DS, 2% and 3%; DoT, 0% and 0%; and MoA, 0% and 0%. CONCLUSION: Both 
      patients and oncology nurses valued OS, ORR, and AEs as the most important 
      treatment attributes for advanced melanoma, followed by PFS, whereas DS, DoT, and 
      MoA were given less value in their treatment decisions. IMPLICATIONS FOR 
      PRACTICE: Oncology nurses and patients have similar views on important treatment 
      considerations for advanced melanoma, which can help build trust in shared 
      decision-making.
FAU - Liu, Frank Xiaoqing
AU  - Liu FX
AD  - Author Affiliations: Merck & Co, Inc, Kenilworth, New Jersey (Drs Liu and 
      Ebbinghaus); Kantar Health, New York, New York (Dr Witt, Ms Beyer, and Mr 
      Basurto); and Mayo Clinic, Jacksonville, Florida (Dr Joseph).
FAU - Witt, Edward A
AU  - Witt EA
FAU - Ebbinghaus, Scot
AU  - Ebbinghaus S
FAU - DiBonaventura Beyer, Grace
AU  - DiBonaventura Beyer G
FAU - Basurto, Enrique
AU  - Basurto E
FAU - Joseph, Richard W
AU  - Joseph RW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Nurs
JT  - Cancer nursing
JID - 7805358
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Attitude of Health Personnel
MH  - Choice Behavior
MH  - Female
MH  - Humans
MH  - Male
MH  - Melanoma/pathology/*therapy
MH  - Middle Aged
MH  - *Oncology Nursing
MH  - Patient Preference/*statistics & numerical data
MH  - Risk Assessment
PMC - PMC6286876
EDAT- 2017/10/28 06:00
MHDA- 2020/01/07 06:00
PMCR- 2018/12/09
CRDT- 2017/10/28 06:00
PHST- 2017/10/28 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2017/10/28 06:00 [entrez]
PHST- 2018/12/09 00:00 [pmc-release]
AID - NCC50288 [pii]
AID - 10.1097/NCC.0000000000000557 [doi]
PST - ppublish
SO  - Cancer Nurs. 2019 Jan/Feb;42(1):E52-E59. doi: 10.1097/NCC.0000000000000557.